BRIDGEWATER, New Jersey, April 3, 2017 /PRNewswire-HISPANIC PR WIRE/ — Sanofi announced today the launch of ACT^® Kids Toothpaste, a new anti-cavity fluoride toothpaste that is specially developed for kids two years of age and older. With its bubble gum and fruit punch flavors, 4 out of 5 parents say ACT Kids Toothpaste motivates their kids to brush their teeth.¹  

Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/8029551-sanofi-launches-act-kids-toothpaste-us/

“We are excited to introduce our first children’s toothpaste into the portfolio of oral care products that ACT currently offers,” said Jennifer Cooper, Associate Director – Oral Care, Sanofi Consumer Health Care. “Our hope is that this new product will help motivate kids to brush and inspire parents to further instill healthy oral care habits at an early age.”

A recent survey found more than half of moms (56%) struggle with getting their kids to brush their teeth, illustrating the need for new oral care products that make this daily battle easier. Additional findings from the recent survey of moms include the following:*

• A majority of moms (73%) say they wish their kids were motivated to brush their teeth instead of seeing it as a chore 
• Nearly 4 in 10 moms (35%) say getting their kids to brush their teeth is one of their most frustrating daily battles, in line with convincing them to eat their vegetables (38%) and putting them to bed at night (40%)
• More than half of moms (52%) say they would give up their “me time” for a month if it meant they never had to battle with their kids again to get them to brush their teeth

“Getting children to brush their teeth well and often can be a challenging battle for parents but it is incredibly important for the prevention of cavities,” said Paul H. Carico, III, DDS with Chattanooga Center for Comprehensive Dentistry. “With flavors kids enjoy and the power of fluoride, which safely strengthens teeth and prevents tooth decay, parents can trust ACT Kids Toothpaste as a new option to help their children maintain a clean, strong smile.”

ACT Kids Toothpaste is rolling out to a variety of retail locations in March-April 2017, including select Walmart, Walgreens, and Target locations. In addition to the toothpaste, the ACT Kids line includes anticavity rinses that can be used after brushing by kids 6 years of age and older for the optimal oral care routine. For more information, visit ACTOralCare.com/ACT-for-Kids. If further assistance is needed, please email [email protected].

*This survey was conducted online using Toluna’s QuickSurveys methodology between February 13, 2017 and February 14, 2017 among 1,150 moms in the USA with children between the ages of two and 12. Respondents for Toluna QuickSurveys are selected from among those who have agreed to participate in Toluna surveys.

Toluna’s SmartSelect_™ methodology was used to promote sample representativeness. SmartSelect relies on statistical matching rather than probability sampling to select survey respondents, based on demographic, attitudinal and behavioral characteristics that match those of the target population. Figures for age, gender, region, race/ethnicity, education and income are also weighted to bring them into line with their actual proportions within the population. Because the sample is based on those who agreed to participate in Toluna surveys, no estimates of theoretical sampling error can be calculated.

About ACT
A trusted leader in mouthwashes for over 30 years, ACT^® offers a broad line of products, including some of the fastest-growing and top-selling mouthwashes, fluoride rinses, lozenges and toothpastes in America. ACT^® Kids products are specially designed to protect and strengthen kids’ developing teeth, including new ACT^® Kids Toothpaste and a variety of anticavity mouthwashes. Visit www.ACTOralCare.com for more information.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

¹ Data on File

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts: